Johnson & Johnson To Present New Findings On IMAAVY For Treatment Of Generalized Myasthenia Gravis Across 15 Novel Abstracts At 2026 MGFA Scientific Session And AANEM Annual Meeting
New two-year findings from the Phase 2/3 long-term extension demonstrate sustained disease control through two years, improvement in daily function and muscle strength, and reductions in corticosteroid use in
Johnson & Johnson will show new test results for a myasthenia gravis medicine. The two year study shows the drug keeps working and helps people use less steroids.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.